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METHODOLOGY

A technique for approximating transition
rates from published survival analyses
Markian A. Pahuta1*, Joel Werier2, Eugene K. Wai2,3, Roy A. Patchell4 and Doug Coyle3

Abstract
Background: Quality-adjusted-life-years (QALYs) are used to concurrently quantify morbidity and mortality within a
single parameter. For this reason, QALYs can facilitate the discussion of risks and benefits during patient counseling
regarding treatment options. QALYs are often calculated using partitioned-survival modelling. Alternatively, QALYs can
be calculated using more flexible and informative state-transition models populated with transition rates estimated
using multistate modelling (MSM) techniques. Unfortunately the latter approach is considered not possible when
only progression-free survival (PFS) and overall survival (OS) analyses are reported.
Methods: We have developed a method that can be used to estimate approximate transition rates from published
PFS and OS analyses (we will refer to transition rates estimated using full multistate methods as true transition rates).
Results: The approximation method is more accurate for estimating the transition rates out of health than the transition rate out of illness. The method tends to under-estimate true transition rates as censoring increases.
Conclusions: In this article we present the basis for and use of the transition rate approximation method. We then
apply the method to a case study and evaluate the method in a simulation study.
Keywords: Cancer, Multistate model, Survival analysis, Quality adjusted life year
Background
Chronic, progressive, and non-communicable diseases
(such as cancer, diabetes, cardiovascular disease and
chronic respiratory disorders) are now the leading cause
of morbidity and mortality around the world. More than
60% of global deaths are attributable to these types of diseases [1]; consequently these diseases now account for up
to 50% of the total healthcare budget in some countries
[2]. Many of these diseases can be conceptualized as consisting of three health states: healthy (h), ill (i), or dead (d)
(Fig. 1).
Treatment decisions for chronic, progressive, and
non-communicable diseases are difficult because interventions can have distinct, and sometimes opposite,
influences on the probability that a patient experiences
a given health state. For example, a therapy (e.g. highrisk cancer surgery) may decrease the risk of death (by
*Correspondence: mark@pahutamd.com
1
Department of Orthopaedic Surgery, Henry Ford Health System,
Detroit, MI, USA
Full list of author information is available at the end of the article

controlling cancer) but may increase the risk of becoming ill (if a post-operative complication occurs). Qualityadjusted-life-years (QALYs) can be used to concurrently
quantify morbidity and mortality within a single parameter [3]. For this reason, QALYs may facilitate the discussion of risks and benefits during patient counseling
regarding treatment options [4]. QALY calculation
requires knowledge of state-membership fractions. These
are the proportion of patients from a defined cohort that
are in a given health state at a given time t. State-membership fractions can be calculated using partitioned-survival modelling or state-transition modelling [5–7].
Partitioned-survival modelling uses data abstracted
from progression-free survival (PFS) curves and overall
survival (OS) curves reported in the literature [7]. PFS
curves show the fraction of the cohort that is healthy over
time t (PFS(t); OS curves show the fraction of the cohort
that is alive (either healthy or ill) over time t (OS(t)). Since
OS curves show the fraction of alive patients, the fraction
of dead patients is simply 1 − OS(t). The fraction of ill
(but alive) patients is the difference between the fraction

© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Fig. 1 State-transition diagram for illness-death model.
State-transition diagram for an illness-death model. The model
consists of three health states: healthy (h), ill (i), and dead (d). Variable
names adjacent to the solid arrows are transition rates (hi , hd ,
and id ). This model is said to be “progressive” because transitions
are irreversible (i.e. unidirectional). The curved arrows indicate that
individuals can remain in a particular state over time. See text for
more details

of alive and healthy patients OS(t) − PFS(t). We will refer
to state-membership fractions calculated in this way as
partitioned-survival fractions [5–7]. In contrast, statetransition modelling applies the results of a multistate
analysis. For the disease shown in Fig. 1, these techniques
would be used to estimate the transition rate (i.e. the
instantaneous risk (or hazard) of moving from one state
to another) from health to illness (h → i), from health
to death (h → d ), and from illness to death (i → d ) [6].
Transition rates can be used compute transition probability matrices to calculate state-membership fractions
(“multistate fractions”). It is important to recognize that
state-transition modelling is based on a set of mutually
exclusive health states (health, illness, death), whereas
partitioned survival modelling is based on non-mutually
exclusive health states (health and illness or death for the
PFS curve, and alive and dead for the OS curve). Partitioned-survival modelling is used when sufficient data for
state-transition modelling is unavailable.
QALY calculations based on partitioned-survival fractions can suffer from two important limitations that
result from the fact that (i) the OS analysis does not consider the survival of ill patients separate from healthy
patients, and (ii) the risk of progressing to illness rather
than death for healthy patients cannot be determined
from PFS analysis. The first limitation of partitioned-survival fractions stems from the difficultly of extrapolating
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partitioned-survival fractions beyond the study’s observation period [6]. This is a significant deficiency because
clinical studies often have a limited observation period
that is of insufficient duration to characterize long-term
clinical outcomes [8–13]. The second limitation of partitioned-survival fractions is that computed QALYs are
not generalizable to patient cohorts whose baseline fractions of healthy, ill and dead patients differs from those
of the study cohort [6]. This is because the OS curve
is a weighted average of OS curves for healthy and ill
patients; therefore, the shape of the curve will change if
the baseline ratio of healthy to ill patients differs. These
two limitations restrict the use of partitioned survival
fractions for decision analysis. These limitations can be
avoided by calculating QALYs using multistate fractions.
Because they are based on granular analyses of all transitions, multistate fractions have several advantages over
partitioned-survival fractions. First, they can be reliably
extrapolated beyond the study observation period [6].
Second, they can be used for decision analysis in cohorts
with baseline characteristics that differ from the original
study cohort [14].
Unfortunately, one cannot usually calculate transition
rates using data abstracted from PFS and OS analyses
[6, 7]. Given the limitations of partitioned-survival fractions and the advantages of multistate fractions, it would
be helpful to obtain transition rates and calculate the latter when one only has access to PFS and OS analyses. We
have developed a method that, under particular conditions, can be used to estimate approximate transition
rates from published PFS and OS analyses (we will refer
to transition rates estimated using full multistate methods as true transition rates).
This article organized as follows. We first present the
basis for and use of the transition rate approximation
method. A case study is then reported in which we apply
transition rate approximation to data from a randomized
controlled trial (RCT) of treatments for metastatic epidural spinal cord compression (MESCC). We then report
a simulation study evaluating the accuracy of the approximation method. In the last section we summarize and
discuss our findings.

Methods
The approximation technique is restricted to three-state
progressive, time-homogenous Markov disease processes such as the one shown in Fig. 1 [15]. Progressive
means that transitions are irreversible (i.e. cannot return
to health from illness). Time-homogenous, means that
transition rates do not change over time. Markov means
that transition rates do not depend on disease history;
in other words, the probability that a patient transitions

Pahuta et al. Cost Eff Resour Alloc

(2019) 17:12

Page 3 of 8

from state x to state y during a particular time period is
independent of their previous health state.
The data needed to use the approximation technique
can be abstracted from most articles reporting PFS and
OS analyses. The number of patients experiencing an
event and number of censored patients in both the PFS
e
c
e and N c ) analyses can be
( Npfs
and Npfs
) and OS ( Nos
os
determined from the article text or patients-at-risk risk
table. To obtain the remaining data points, PFS and OS
KM curves need to be digitized. Digitized KM curves can
then be used to reconstruct individual patient data using
validated algorithms to determine the event times in the
PFS and OS analyses [16]. The approximation technique
requires that we make note of the maximum observation
time (event or censoring) in the PFS and OS analyses (τpfs
and τos respectively). The area under the PFS and OS
curves ( AUCpfs and AUCos respectively) are calculated by
summing the area under each step of the KM curve.
We denote h → i, h → d , and i → d transition rates as
hi , hd , and id . For the time-homogenous disease processes (i.e. constant transition rates), exit times from the
(i) healthy state (i.e. h → i or h → d transition) and (ii) ill
state (i.e. i → d transition) are exponentially distributed.
Furthermore, once a patient exits health, the probability
that they make an h → d transition is

ρ=

ρ≈

(2)

To approximate id we need to use information gathered
from the OS analysis. It is more challenging to define an
exact formula for the restricted mean overall survival
time (RMOST−τ ) than form the RMPFST−τ because
exit from the alive state (i.e. healthy or ill) is defined by
a mixture of two exponential distributions: exit from
health and exit from illness. However, if we know the
death times oei and censoring times ocj for a cohort of
e who had an observed event, and N c
alive patients, Nos
os
who were right censored, we can approximate RMOST−τ
truncated to τos, RMOST−τos , using inverse probability
weighting [22]

RMOST −τos


c
e
Nos
Nos
e + Nc � �
�
N
os
os
≈
ocj 
oei +
e
Nos
j=1
i=1
�
�
1
.
×
e + Nc
Nos
os


�

e

Eos =

We will refer to ρ as the risk of death for healthy patients.
As there are only two possible transitions out of health,
the probability that a transition out of the health state is
an h → i transition is 1 − ρ.
The mean time of exit from the healthy state (i.e. mean
progression-free survival time) is a biased measure in
the presence of right censoring [17]. Instead we calculate the restricted mean progression free-survival time
(RMPFST−τ ) which is interpreted as the mean progression-free survival time if observation is restricted to a
truncation time τ [18]. Since the exit time from health is
exponentially distributed, the RMPFST−τ can be calculated as

1 − e−(hi +hd )τ
hi + hd

.

(1)

By definition, the area under the PFS curve is equal to
RMPFST−τ when τ is set to the maximum observation
time in the PFS analysis, τpfs [19, 20]. Using Formula 1,
we can then numerically solve for hi + hd using standard algorithmic methods [21]. Simultaneous events in the
PFS and OS analyses indicate h → d transitions. Therefore, we can approximate the risk of death for healthy
patients as

(3)

Next, we determine the total person-time of observation
in the OS analysis

hd
hi + hd

RMPFST−τ =

Nsimul
e .
Npfs

Nos


c

oei

+

i=1

Nos


ocj .

(4)

j=1

If censoring times are not denoted on the OS curve, it is
not possible to determine ocj . However, we can rearrange
Formula 3 to yield
e

c

Nos


ocj

≈ RMOST

−τos

j=1



e
Nos

c
+ Nos



−

Nos

i=1

oei



e + Nc 
Nos
os
.
e
Nos

If we substitute this relationship into Formula 4 we obtain
e

Eos ≈

Nos

i=1

e
 e
Nos
c 
 
 e
Nos + Nos
c
oei
oei + RMOST−τos Nos
+ Nos
−
e
Nos

i=1

e

≈ RMOST

−τos



e
Nos


c

+ Nos +

Nos

i=1

oei

Ne + Nc
1 − os e os
Nos





(5)

We can repeat the same calculations using the corresponding data from the PFS analysis to approximate total
person-time of observation in the OS analysis, Epfs. We
then approximate the total person-time of observation in
the ill state as

(6)
If we make the assumption that the number of i → d
transitions is
Eill ≈ Eos − Epfs .
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e
Nid ≈ Nos
− Nsimul ,

we can compute [23]

id ≈

Nid
.
Eill
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(7)
(8)

Results
MESCC case study

To evaluate whether the approximation method can generate reasonable results, we compared approximate transitions rates against a gold standard of true transition
rates estimated from real study data.
Patchell et al. [24] conducted a randomized controlled
trial (RCT) comparing modern surgery and radiotherapy
(mS+RT) versus radiotherapy alone (RT-alone) for the
treatment of metastatic epidural spinal cord compression
(MESCC). MESCC occurs when cancer metastasizes to
the spine which and can lead to loss of ambulation from
paralysis. MESCC can be modelled as in Fig. 1 if we consider ability to ambulate as the healthy state h and the
inability to ambulate due to neurologic dysfunction as
the ill state i. True transition rates were estimated using
individual patient data provided by the study authors.
To eliminate the potential for transcription error and
inaccuracy in individual patient data reconstruction,
we used actual individual patient data to generate the
data listed in Table 1. We estimated true transition rates
using the Bayesian modeling language Stan, [25] run
through the statistical programming language R (Additional file 1: Appendix A) [26]. The effect of mS+RT was

parametrized as a log-hazard ratio for each RT-alone
transition rate.
Prior to comparing true and approximate transition
rates, we conducted non-parametric multistate analysis
to assess whether our assumed model (progressive, timehomogenous and Markov) was appropriate for MESCC.
Non-parametric multistate fractions were estimated
from individual patient data from the MESCC RCT using
the etm library [27] run through the statistical programming language R [26]. We compared non-parametric
multistate fractions and multistate fractions calculated
from true transition rates. Goodness-of-fit tests for true
multistate analysis of data observed with exact transition
times affected by right censoring have not been developed [5]. We therefore used informal graphical methods.
Plots comparing proper non-parametric multistate
and proper parametric multistate fractions showed good
agreement, and no evidence of systematic deviation
(Figs. 2 and 3). Therefore, a progressive time-homogenous three-state Markov model is appropriate for the
MESCC RCT data and true transition rates can serve as
an appropriate comparator to evaluate approximate transition rates. Calculations for the mS+RT arm are shown
in Additional file 1: Appendix B.
The true transition rates shown in Table 2 provides
useful insights into the impact of treatment. mS+RT
prolongs ambulation with a statistically significant hazard ratio of 0.53 (95% CrI: 0.30, 0.94) on the total transition rate for exit from the ambulatory state (hi + hd ).
For patients making a transition out of the ambulatory
state, the risk of death was similar with both treatments:

Table 1 Data abstracted from MESCC RCT PFS and OS analyses
Description

RT-alone arm

mS+RT arm

e
Npfs

Total number of PFS events

17

31

c
Npfs

Total number of patients censored from PFS analysis

5

6

e
Npfs

Person-time of PFS observation

7.02 years

27.22 years

τpfs

Maximum observation time in the PFS analysis

2.97 years

5.25 years

AUCpfs

Area under PFS curve

0.63

1.16

e
Nos

Total number of OS events

44

45

c
Nos

Total number of patients censored from OS analysis

1

3

τos

Maximum observation time in the OS analysis

2.99 years

5.25 years

e
Nos


Person-time of OS observation

24.17 years

35.89 years

Area under OS curve

0.62

0.98

10

19

PFS analysis



i=1

pei

OS analysis

i=1

oei

AUCos

Synthesis of PFS and OS analyses
Nsimul

Total number of simultaneous events in PFS and OS curves
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Fig. 2 Comparison of state-membership fractions, RT-alone arm. State-membership fractions for RT-alone arm. Non-parametric multistate fractions,
solid black line. Parametric multistate fractions based on true transition rates, small dashed red line

relative risk 1.07 (95% CrI, 0.65 – 1.75). mS+RT tended
to increase the mortality rate for non-ambulatory
patients, hazard ratio for id of 1.61 (95% CrI: 0.89, 2.66),
but this effect was not statistically significant.
All approximate transition rates lay within the 95%
credible intervals for true transition rates. There was no
consistent direction of error indicating the approximation method does not consistently under-or over-estimate true transition rates.
Simulation study

To assess the validity of the approximation strategy in a
wider set of conditions, we conducted a simulation study
to assess the impact of censoring on the accuracy of the
approximation method for (hi + hd ), ρ , and id.
Data were generated randomly for a three-state progressive, time-homogenous Markov disease process with
parameters similar to those for the mS+RT arm from
the MESCC trial. A simulated cohort of 100 patients,
75 of which were healthy at baseline, was created with
hi = 0.33, hd = 0.53, id = 3.28. Events times were
independently censored using a uniform distribution
to achieve all combinations of 0, 2, 5, and 10 patients

censored from the OS and PFS analysis. 100 000 replications were generated for each set of simulation
conditions.
We calculated the mean error (ME), mean absolute
error (MAE), mean percentage error (%ME), and mean
absolute percentage error (%MAE) for each set of simulation conditions (Tables 3, 4, and 5). ME and %ME are
a measure of the direction of bias (systematic over- or
underestimation). MAE and %MAE are a measure of the
magnitude of error, regardless of direction.
The approximation method tended to underestimate
(hi + hd ) and ρ as the censoring rate increased, however
the bias was small with %ME under 3% in all censoring
conditions. Even under no censoring, the approximation method was imprecise with a relatively high MAE
and %MAE; increasing censoring did not significantly
decrease precision.
The approximation method tended to underestimate
id as the censoring rate increased, however the bias was
small with %ME under 3% in all censoring conditions.
Even under no censoring, the approximation method was
imprecise with a relatively high MAE and %MAE; increasing censoring did not significantly decrease precision.
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Fig. 3 Comparison of state-membership fractions, mS+RT arm. State-membership fractions for arm. Non-parametric multistate fractions, solid
black line. Parametric multistate fractions based on true transition rates, small dashed red line

Table 2 Comparison of true and approximate transition rates and hazard ratios for MESCC RCT
Transition rates
True (95% CrI)

Hazard ratios
Approximate

Error

% Error

− 0.01

− 1.52

+ 0.07

+ 3.30

True (95% CrI)

Approximate

Error

% Error

+ 0.01

+ 1.54

+ 0.08

+ 5.22

RT-alone group
hi

0.66 (0.27, 1.20)

0.65

hd

1.00 (0.50, 1.67)

0.92

id

2.12 (1.40, 2.98)

2.19

mS+RT group

+ 0.08

− 8.00

hi

0.33 (0.17, 0.54)

0.33

0.00

0.00

0.50 (0.21, 1.40)

0.51

hd

0.53 (0.32, 0.80)

0.52

0.56

3.28 (2.09, 4.69)

3.71

− 1.89

0.55 (0.26, 1.16)

id

− 0.01

1.61 (0.89, 2.66)

1.62

+ 0.43

+ 13.11

+ 0.02

+ 2.77

CrI, Bayesian credible interval. Error, Approximate − True. % Error, (Approximate − True) ÷ True

The approximation method tended to underestimate
id as the censoring rate increased, however the bias was
small with %ME under 3% in all censoring conditions.
Even under no censoring, the approximation method was
imprecise with a relatively high MAE and %MAE; increasing censoring did not significantly decrease precision.

Discussion
Although chronic, progressive, and non-communicable
diseases chronic diseases affect both patients’ survival
and quality-of-life, interventions may impact on these
two outcomes differentially. QALYs can simplify decision-making and counselling regarding treatment options
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Table 3 Simulation results for (hi + hd )

requires that three elements be abstracted from each of
the PFS and OS analyses: (i) total number of events, (ii)
total number of censored patients, and (iii) event times.
Approximate transition rates provide a reasonable
estimate of true transition rates estimated using full
multistate methods. For the MESCC RCT case study, all
approximate transition rates lay within the 95% Bayesian credible intervals for true transition rates. The simulation study indicates that the approximation method is
relatively unbiased and precise for estimating the transition rate out of health (hi + hd ) and the risk of death for
healthy patients ρ.
It is important to recognize that our techniques only
apply to a time-homogenous progressive three-state irreversible disease process. Time-homogeneity is violated if
the transition rates change with time (i.e. any parametric model aside from the exponential) or depend on the
amount of time spent in the preceding health state (nonMarkov phenomenon) [28]. Irreversibility is violated
if patients can become healthy after being ill [15]. Our
approximation approach can be scaled-up to more complex (e.g. reversible transitions, > 3 health states) disease
models, however, the formulas will become more complex. Furthermore, as was done in this article, it would
be necessary to validate the scaled-up approximation
approach to evaluate for bias.

# Censored
OS

# Censored
PFS

ME

MAE

%ME

% MAE

0

0

0.00

0.08

0.11

9.34

5

8

0.10

15

− 7.33

11.19

5

− 0.06

5

30

0.21

15

− 24.69

24.86

10

− 0.21

10

30

0.21

15

− 23.69

23.93

20

− 0.20

20

30

0.19

30

− 22.32

22.65

40

− 0.19

− 0.10

0.12

− 0.10

0.12

− 0.08

0.11

− 0.17

0.17

− 12.18

14.09

− 11.50

13.70

− 9.85

12.74

− 19.30

20.01

Table 4 Simulation results for ρ
# Censored
OS

# Censored
PFS

0

0

5

8

5

15

5

30

10

15

10

30

20

15

20

30

40

30

ME

MAE

− 0.00

0.04

− 0.00

0.05

− 0.00

0.05

− 0.00

0.06

− 0.01

0.05

− 0.01

0.06

− 0.02

0.05

− 0.02

0.06

− 0.06

0.08

%ME
− 0.01

− 0.66

− 0.62

− 0.58

− 1.42

− 1.33

− 3.75

− 3.05

− 9.38

% MAE
7.27
7.90
8.24
9.50
8.30
9.52
8.70
9.74
12.21

Table 5 Simulation results for id
# Censored # Censored ME
OS
PFS

MAE

%ME

% MAE

0

0

0.07

0.41

2.25

12.42

5

8

0.56

15

− 12.59

17.19

5

− 0.41

5

30

71.28

15

− 2114.42

2173.07

10

− 69.35

10

30

2.36

20

15

− 0.73

20

30

40

30

− 0.55

0.72

− 0.52

0.70

− 4.54

4.60

0.79

2.75

− 1.89

1.90

− 16.81

21.92

− 15.96

21.35

− 138.32

140.30

24.22

83.88

− 57.67

57.88

− 22.13

72.08

[4]. For clinicians and decision makers, QALYs calculated
using multistate fractions are useful because they can be
used to extrapolate long-term quality-of-life and to conduct rich decision analysis. Unfortunately, one cannot
usually calculate multistate fractions from PFS and OS
curves [5–7].
In this paper, we presented a technique for approximating transition rates, which can be used to calculate multistate fractions, from PFS and OS analysis. Our technique

Conclusions
In this paper, we have demonstrated that transition
rates can be approximated from published PFS and OS
analyses. The approximation method is more accurate
for estimating the transition rates out of health than the
transition rate out of illness. The method tends to underestimate true transition rates as censoring increases;
therefore, approximate transition rates are not a substitute for true transition rates estimated with full multistate methods. However, when proper multistate analysis
is not available, approximate transition rates can guide
probabilistic modeling and enhance QALY analysis if one
considers and accounts for the limitations of the approximation method.
Additional files
Additional file 1: Appendix A. Transition parameters for an illness-death
model. Appendix B. Multistate estimation of transition rates.
Abbreviations
MAE: mean absolute; %MAE: mean absolute percentage error; ME: mean
error; %ME: mean percentage error; MESCC: metastatic epidural spinal cord
compression; mS+RT: modern surgery followed by radiotherapy; OS: overall
survival; PFS: progression-free survival; QALY: quality-adjusted life-years; RCT:
randomized controlled trial; RT-alone: radiotherapy alone.

Pahuta et al. Cost Eff Resour Alloc

(2019) 17:12

Page 8 of 8

Acknowledgements
None.
Authors’ contributions
MAP and DC conceived and designed this work and interpreted the data. RAP
conducted the MESCC RCT. All authors contributed to drafting and revising
this work. All authors read and approved the final manuscript.
Funding
Not applicable.
Availability of data and materials
The datasets used and/or analysed during the current study are available from
the corresponding author on reasonable request.

8.
9.
10.
11.
12.

Competing interests
The authors declare that they have no competing interests.

13.

Ethics approval and consent to participate
Not applicable.

14.

Consent for publication
Not applicable.
Author details
1
Department of Orthopaedic Surgery, Henry Ford Health System, Detroit, MI,
USA. 2 Division of Orthopaedic Surgery, The University of Ottawa, Ottawa, ON,
Canada. 3 School of Epidemiology and Public Health, The University of Ottawa,
Ottawa, ON, Canada. 4 Departments of Neurology and Neurosurgery, University of Kentucky Medical Center, Lexington, KY, USA.
Received: 12 March 2019 Accepted: 25 June 2019

15.
16.
17.
18.
19.
20.

References
1. The World Health Organization. Global status report on noncommunicable diseases. Geneva; 2010, p. 9–31. http://www.who.int/nmh/publicatio
ns/ncd_report_chapter1.pdf. Accessed 10 Jan 2019.
2. Muka T, Imo D, Jaspers L, Colpani V, Chaker L, van der Lee SJ, Mendis
S, Chowdhury R, Bramer WM, Falla A, Pazoki R, Franco OH. The global
impact of non-communicable diseases on healthcare spending and
national income: a systematic review. Eur J Epidemiol. 2015;30(4):251–77.
3. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford:
Oxford University Press; 2005, p. 400. http://www.amazon.com/Metho
ds-Economic-Evaluation-Health-Programmes/dp/0198529457. Accessed
10 Jan 2019.
4. Kind P, Lafata JE, Matuszewski K, Raisch D. The use of QALYs in clinical and patient decision-making: issues and prospects. Value Health.
2009;12(Suppl 1):27–30.
5. Titman AC, Sharples LD. Model diagnostics for multi-state models. Stat
Methods Med Res. 2010;19(6):621–51.
6. Woods B, Sideris E, Palmer S, Latimer N, Soares M. Partitioned survival
analysis for decision modelling in health care: a critical review. Technical
report June, NICE decision support unit, Sheffield; 2017. http://schar
r.dept.shef.ac.uk/nicedsu/wp-content/uploads/sites/7/2017/06/Partitione
d-Survival-Analysis-final-report.pdf. Accessed 10 Jan 2019.
7. Williams C, Lewsey JD, Mackay DF, Briggs AH. Estimation of survival
probabilities for use in cost-effectiveness analyses: a comparison of
a multi-state modeling survival analysis approach with partitioned

21.
22.
23.

24.

25.
26.
27.
28.

survival and markov decision-analytic modeling. Med Decis Making.
2017;37(4):427–39.
Hawkins N, Grieve R. Extrapolation of survival data in cost-effectiveness
analyses: the need for causal clarity. Med Decis Making. 2017;37(4):337–9.
Bagust A, Beale S. Survival analysis and extrapolation modeling of
time-to-event clinical trial data for economic evaluation: an alternative
approach. Med Decis Making. 2014;34(3):343–51.
Latimer NR. Survival analysis for economic evaluations alongside clinical
trials-extrapolation with patient-level data: inconsistencies, limitations,
and a practical guide. Med Decis Making. 2013;33(6):743–54.
Grieve R, Hawkins N, Pennington M. Extrapolation of survival data in costeffectiveness analyses: improving the current state of play. Med Decis
Making. 2013;33(6):740–2.
Connock M, Hyde C, Moore D. Cautions regarding the fitting and
interpretation of survival curves: examples from NICE single technology
appraisals of drugs for cancer. Pharmacoeconomics. 2011;29(10):827–37.
Tappenden P, Chilcott J, Ward S, Eggington S, Hind D, Hummel S. Methodological issues in the economic analysis of cancer treatments. Eur J
Cancer. 2006;42(17):2867–75.
Andersen PK, Abildstrom SZ, Rosthøj S. Competing risks as a multi-state
model. Stat Methods Med Res. 2002;11(2):203–15.
Hougaard P. Multi-state models: a review. Lifetime Data Anal.
1999;5(3):239–64.
Wan X, Peng L, Li Y. A review and comparison of methods for recreating
individual patient data from published Kaplan-Meier survival curves for
economic evaluations: a simulation study. PLoS ONE. 2015;10(3):0121353.
Datta S. Estimating the mean life time using right censored data. Stat
Methodol. 2005;2(1):65–9.
Lee CH, Ning J, Shen Y. Analysis of restricted mean survival time for
length-biased data. Biometrics. 2018;74(2):575–83.
Royston P, Parmar MK. Restricted mean survival time: an alternative to the
hazard ratio for the design and analysis of randomized trials with a timeto-event outcome. BMC Med Res Methodol. 2013;13(1):152.
Zhao L, Claggett B, Tian L, Uno H, Pfeffer MA, Solomon SD, Trippa L, Wei
LJ. On the restricted mean survival time curve in survival analysis. Biometrics. 2016;72(1):215–21.
Brent RP. Algorithms for minimization without derivatives. New Jersey:
Pretince-Hall; 1973. p. 195.
Halpern EF. Behind the numbers: inverse probability weighting. Radiology. 2014;271(3):625–8.
Welton NJ, Ades AE. Estimation of markov chain transition probabilities
and rates from fully and partially observed data: uncertainty propagation, evidence synthesis, and model calibration. Med Decis Making.
2005;25(6):633–45.
Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, Mohiuddin
M, Young B. Direct decompressive surgical resection in the treatment of
spinal cord compression caused by metastatic cancer: a randomised trial.
Lancet. 2005;366(9486):643–8.
Stan Development Team. The Stan Core Library, Version 2.17.0; 2017.
http://mc-stan.org/.
R Core Team. R: a language and environment for statistical computing.
Vienna: R Foundation for Statistical Computing; 2018. http://www.r-proje
ct.org/http://www.r-project.org.
Allignol A, Schumacher M, Beyersmann J. Empirical transition matrix of
multi-state models: the etm package. J Stat Softw. 2011;38(4):1–5.
Kalbfleisch JD, Pretince RL. The statistical analysis of failure time data. 2nd
ed. Hoboken: Wiley; 2002. p. 439.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

